Published in Breast Cancer Res Treat on January 10, 2008
Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging (2014) 1.49
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol (2005) 3.09
Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation (2008) 2.72
Association between lipid profile and risk of atrial fibrillation. Circ J (2011) 2.26
Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer. World J Surg (2009) 2.02
Single-incision laparoscopic cholecystectomy: single institution experience and literature review. World J Gastroenterol (2010) 1.78
Expression of insulin-like growth factor 1 receptor in primary breast cancer: immunohistochemical analysis. Hum Pathol (2004) 1.77
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol (2004) 1.73
Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci (2010) 1.72
Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1. J Clin Endocrinol Metab (2004) 1.63
Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen. Eur Urol (2007) 1.56
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat (2011) 1.55
Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients. J Clin Endocrinol Metab (2004) 1.55
Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol (2009) 1.52
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med (2013) 1.46
Norovirus pathway in water environment estimated by genetic analysis of strains from patients of gastroenteritis, sewage, treated wastewater, river water and oysters. Water Res (2005) 1.42
Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J (2009) 1.41
Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma. Anticancer Res (2003) 1.37
Prognostic factors and clinical outcomes in patients with leptomeningeal metastasis from solid tumors. J Neurooncol (2008) 1.28
Laparoendoscopic single site partial resection of the stomach for gastrointestinal stromal tumor. Surg Laparosc Endosc Percutan Tech (2010) 1.26
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat (2006) 1.25
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. Jpn J Cancer Res (2002) 1.25
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol (2014) 1.18
A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol (2009) 1.11
Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci (2012) 1.10
Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer (2010) 1.09
Reversible secondary pseudohypoaldosteronism. Pediatr Nephrol (2003) 1.09
ST-segment abnormalities and premature complexes are predictors of new-onset atrial fibrillation: the Niigata preventive medicine study. Am Heart J (2006) 1.09
Mastermind-like domain-containing 1 (MAMLD1 or CXorf6) transactivates the Hes3 promoter, augments testosterone production, and contains the SF1 target sequence. J Biol Chem (2007) 1.08
General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer (2005) 1.08
Homozygous mutation of P450 side-chain cleavage enzyme gene (CYP11A1) in 46, XY patient with adrenal insufficiency, complete sex reversal, and agenesis of corpus callosum. J Clin Endocrinol Metab (2006) 1.06
Physician-patient communication and patient satisfaction in Japanese cancer consultations. Soc Sci Med (2002) 1.06
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol (2008) 1.05
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat (2009) 1.05
Brain metastases in patients who receive trastuzumab-containing chemotherapy for HER2-overexpressing metastatic breast cancer. Int J Clin Oncol (2009) 1.03
Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer (2009) 1.02
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer. Int J Clin Oncol (2009) 1.01
The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J (2003) 1.01
Fanconi syndrome caused by sodium valproate: report of three severely disabled children. Eur J Paediatr Neurol (2002) 1.01
Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial. Support Care Cancer (2012) 1.00
Single-incision laparoscopic hernioplasty for obturator hernia. Surg Laparosc Endosc Percutan Tech (2010) 1.00
Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol. Breast Cancer (2006) 0.99
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol (2010) 0.98
Metabolic syndrome and risk of development of chronic kidney disease: the Niigata preventive medicine study. Diabetes Metab Res Rev (2010) 0.97
Successful cure of dermatomyositis after treatment of nonseminomatous testicular cancer. Int J Urol (2005) 0.96
Primary tumor resection improves the survival of younger patients with metastatic breast cancer. Oncol Rep (2009) 0.96
Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J (2012) 0.96
The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol (2005) 0.96
Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res (2002) 0.95
Associations among baseline variables, treatment-related factors and health-related quality of life 2 years after breast cancer surgery. Breast Cancer Res Treat (2011) 0.95
The notorious "drug lag" for oncology drugs in Japan. Invest New Drugs (2011) 0.95
[A case of renal cell carcinoma associated with idiopathic thrombocytopenic purpura]. Hinyokika Kiyo (2005) 0.95
Immunohistochemical profiles of brain metastases from breast cancer. J Neurooncol (2008) 0.94
A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol Oncol (2012) 0.94
Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells. Free Radic Res (2011) 0.94
Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur J Dermatol (2011) 0.94
Influence of the severity of obstructive sleep apnea on heart rate. J Cardiol (2010) 0.93
An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn J Clin Oncol (2006) 0.93
Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci (2010) 0.93
Regional Differences in Prevalence of Macrolide Resistance among Pediatric Mycoplasma pneumoniae Infections in Hokkaido, Japan. Jpn J Infect Dis (2015) 0.93
Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist (2009) 0.92
Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J (2005) 0.92
A report of 2 cases of transient mid-ventricular ballooning. Int J Cardiol (2007) 0.92
A new electrocardiographic criterion to differentiate between Takotsubo cardiomyopathy and anterior wall ST-segment elevation acute myocardial infarction. Am J Cardiol (2011) 0.92
[Guidelines for proper use of antineoplastic agents. Gynecologic cancer]. Gan To Kagaku Ryoho (2002) 0.91
A nationwide attempt to standardize growth hormone assays. Horm Res (2005) 0.90
N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor. Cancer Sci (2008) 0.90
FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Horm Cancer (2011) 0.90
Current trends and controversies over pre-operative chemotherapy for women with operable breast cancer. Jpn J Clin Oncol (2007) 0.90
Clinical outcomes of adult and childhood rhabdomyosarcoma treated with vincristine, d-actinomycin, and cyclophosphamide chemotherapy. J Cancer Res Clin Oncol (2012) 0.90